Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bullous Pemphigoid

Bullous Pemphigoid Abstract To the Editor.— The paper by Eng and Moncada1 is a clear presentation of the problem of histologic differentiation between bullous pemphigoid (BP) and dermatitis herpetiformis. Unfortunately, the tabulated criteria for diagnosis further potentiate, without adequate substantiation, the erroneous concept that if it responds to sulfapyridine or dapsone, it isn't pemphigoid. In a recent review of the Mayo Clinic experience with BP,2 it was noted that a number of these patients were satisfactorily treated with sulfapyridine and a few with dapsone. These drugs are not as uniformly effective in BP as are the corticosteroids, but in view of the relative complications and side effects, the former drugs definitely deserve a trial. A satisfactory response to sulfapyridine or dapsone should never be construed as evidence negating the diagnosis of BP. References 1. Eng AM, Moncada B: Bullous pemphigoid and dermatitis herpetiformis . Arch Dermatol 110:51-57, 1974.Crossref 2. Stone SP, Schroeter AL: Bullous pemphigoid and systematic malignancy . Read before the Section on Dermatology at the 123rd annual convention of the American Medical Association, Chicago, 1974 . http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Bullous Pemphigoid

Abstract

Abstract To the Editor.— The paper by Eng and Moncada1 is a clear presentation of the problem of histologic differentiation between bullous pemphigoid (BP) and dermatitis herpetiformis. Unfortunately, the tabulated criteria for diagnosis further potentiate, without adequate substantiation, the erroneous concept that if it responds to sulfapyridine or dapsone, it isn't pemphigoid. In a recent review of the Mayo Clinic experience with BP,2 it was noted that a number of these patients...
Loading next page...
 
/lp/american-medical-association/bullous-pemphigoid-j36ya5ZwLx
Publisher
American Medical Association
Copyright
Copyright © 1974 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1974.01630110090038
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.— The paper by Eng and Moncada1 is a clear presentation of the problem of histologic differentiation between bullous pemphigoid (BP) and dermatitis herpetiformis. Unfortunately, the tabulated criteria for diagnosis further potentiate, without adequate substantiation, the erroneous concept that if it responds to sulfapyridine or dapsone, it isn't pemphigoid. In a recent review of the Mayo Clinic experience with BP,2 it was noted that a number of these patients were satisfactorily treated with sulfapyridine and a few with dapsone. These drugs are not as uniformly effective in BP as are the corticosteroids, but in view of the relative complications and side effects, the former drugs definitely deserve a trial. A satisfactory response to sulfapyridine or dapsone should never be construed as evidence negating the diagnosis of BP. References 1. Eng AM, Moncada B: Bullous pemphigoid and dermatitis herpetiformis . Arch Dermatol 110:51-57, 1974.Crossref 2. Stone SP, Schroeter AL: Bullous pemphigoid and systematic malignancy . Read before the Section on Dermatology at the 123rd annual convention of the American Medical Association, Chicago, 1974 .

Journal

Archives of DermatologyAmerican Medical Association

Published: Nov 1, 1974

References